• Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - January 22, 2020
    Zacks

    Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - January 22, 2020

    The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

  • Garmin to Gain Traction Among Golfers With Approach S62 Watch
    Zacks

    Garmin to Gain Traction Among Golfers With Approach S62 Watch

    Garmin (GRMN) unveils a GPS smartwatch, Approach S62, to expand its share in the wearables market.

  • Powerful Proof Anyone Can Invest for an Early Retirement - January 22, 2020
    Zacks

    Powerful Proof Anyone Can Invest for an Early Retirement - January 22, 2020

    Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

  • Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
    Zacks

    Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

    Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.

  • 3 Retailers That Made the Most of the 2019 Holiday Season
    Zacks

    3 Retailers That Made the Most of the 2019 Holiday Season

    Holiday season and retail are synonymous. A sturdy labor market, rising income and improving consumer confidence worked in favor of retailers.

  • Here's Why You Should Add DexCom (DXCM) to Your Portfolio
    Zacks

    Here's Why You Should Add DexCom (DXCM) to Your Portfolio

    DexCom (DXCM) expects its strong product portfolio to consistently drive top line.

  • Things to Note Ahead of Spectrum Brands' (SPB) Q1 Earnings
    Zacks

    Things to Note Ahead of Spectrum Brands' (SPB) Q1 Earnings

    Spectrum Brands' (SPB) fiscal first-quarter performance is likely to have benefited from Global Productivity Improvement Plan and robust brand portfolio.

  • Garmin (GRMN) Expands in Outdoor Segment With tactix Delta
    Zacks

    Garmin (GRMN) Expands in Outdoor Segment With tactix Delta

    Garmin (GRMN) has been making significant investments in the outdoor segment, which in turn helps it to develop a solid product line.

  • Has NIKE (NKE) Outpaced Other Consumer Discretionary Stocks This Year?
    Zacks

    Has NIKE (NKE) Outpaced Other Consumer Discretionary Stocks This Year?

    Is (NKE) Outperforming Other Consumer Discretionary Stocks This Year?

  • Foot Locker Declines 12% in 3 Months: Can the Stock Rebound?
    Zacks

    Foot Locker Declines 12% in 3 Months: Can the Stock Rebound?

    Foot Locker's (FL) soft fourth-quarter fiscal 2019 view is hurting investors' sentiments. Nevertheless, its focus on expanding international and digital platforms might aid performance.

  • Financial Times

    Can we ever trust Google with our health data?

    Google hopes that one day it might be able to save your life. Google’s broader health mission was outlined at a conference in San Francisco earlier this month, where its top doctor set out to show why the company may be the most ambitious of the many trying to use technology to transform healthcare. “We have 10 companies with 1bn users and five with 5bn or some insane numbers,” said David Feinberg.

  • Nike (NKE) Up 3.3% Since Last Earnings Report: Can It Continue?
    Zacks

    Nike (NKE) Up 3.3% Since Last Earnings Report: Can It Continue?

    Nike (NKE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Beyoncé’s Ivy Park launch could boost Adidas more than Kanye West did with Yeezy's
    Yahoo Finance

    Why Beyoncé’s Ivy Park launch could boost Adidas more than Kanye West did with Yeezy's

    The relaunch of Beyoncé’s athleisure brand with Adidas is finally here.

  • Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy
    Zacks

    Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy

    Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • 2019 Holiday Retail Sales Rise 4.1%, Online a Key Driver
    Zacks

    2019 Holiday Retail Sales Rise 4.1%, Online a Key Driver

    A sturdy labor market, rising income and improving confidence certainly encouraged consumers to spend more. While bargain hunters did hit the streets, enthusiasm for online shopping was palpable.

  • Online Shoppers Help End 2019 Holiday Season on a Strong Note
    Zacks

    Online Shoppers Help End 2019 Holiday Season on a Strong Note

    The 2019 holiday season mirrors gains from increased investments and opportunities in the retail sector. The online channel continues to be the preferred shopping medium for customers.

  • Tractor Supply Expands Feed Products With Triple Crown Launch
    Zacks

    Tractor Supply Expands Feed Products With Triple Crown Launch

    Tractor Supply (TSCO) is set to launch Triple Crown premium horse feed products. The move is likely to aid the top line and revive the stock's performance.

  • Here's Why Steven Madden (SHOO) is a Solid Investment Option
    Zacks

    Here's Why Steven Madden (SHOO) is a Solid Investment Option

    Steven Madden's (SHOO) consistent expansion efforts and robust wholesale business position it well for growth.

  • Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
    Zacks

    Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

    Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Diabetes Management Gains FDA Attention: 3 Stocks in Focus
    Zacks

    Diabetes Management Gains FDA Attention: 3 Stocks in Focus

    The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

  • Financial Times

    Let athletes enjoy their high-tech footwear

    Of the hundreds of thousands of part-time athletes lining up for a park run this weekend, at least some will sport the latest Nike Vaporfly shoes. Fellow runners will regard them with a mixture of envy, disdain — “they look ridiculous” was one Financial Times athlete’s verdict on the fluorescent, chunky-heeled footwear — and, increasingly, suspicion. The top-of-the-range ZoomX Vaporfly Next%, which retails for £240, is living up to Nike’s billing as “the fastest shoe we’ve ever made”.

  • Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results
    Zacks

    Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

    Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.

  • Crocs Hits New 52-Week High: Here's What Driving the Stock
    Zacks

    Crocs Hits New 52-Week High: Here's What Driving the Stock

    Increased demand for clog shoes along with solid e-commerce and retail comps are likely to keep Croc's (CROX) stellar show on.

  • How your Fitbit can tell if you're getting sick
    Reuters Videos

    How your Fitbit can tell if you're getting sick

    The Fitbit on your wrist can not only track your exercise habits, but it can also help tell if you're coming down with the flu - and warn health authorities to get ready to help you recover. A study in the U.S. found that heart rate and sleep data from the wearable fitness trackers, can predict and alert public health officials to real-time outbreaks of the flu more accurately than current surveillance methods. Data from more than 47,000 Fitbit users in five American states revealed that predictions of flu outbreaks in those areas were better - and faster. Traditional surveillance reports can take up to three weeks, meaning response measures, such as deploying vaccines or anti-virals, and advising patients on when to stay home, can take longer. Previous studies using crowd-sourced data, such as Google Flu Trends and Twitter have experienced variable levels of success. Experts say that's because it's impossible to separate people with flu from people who search online about it - due to the media and public attention present during outbreaks. The World Health Organization estimates that as many as 650,000 people die worldwide of respiratory conditions linked to seasonal flu every year.

  • Nike can gain from Vaporfly controversy: analysts
    Reuters Videos

    Nike can gain from Vaporfly controversy: analysts

    The running world is awaiting a decision by governing body World Athletics over what to do about Nike's Vaporfly shoe, a sneaker that has played a starring role in two of the biggest distance-running achievements last year. A sub two-hour marathon by Eliud Kipchoge and a record-breaking run by Brigid Kosgei. Their stunning performances have sparked heated debate over whether their shoes gave them an unfair advantage. And now, a group at World Athletics is examining what to do about the high-tech sneakers. Among the options facing the organization is to impose a wholesale ban on the shoes or take more limited measures to deal with their carbon plate and foam sole technology. Independent studies have concluded that the shoes improve metabolic efficiency by 4%, though that does not necessarily mean a runner will be 4% faster. All Nike says on its website that the shoe, which will run you $250, has a "built-in secret weapon." But despite all the controversy, analysts tell Reuters the publicity could actually boost sales, especially among amateur runners looking for more spring in their step, since they wouldn't be affected by any ban.